scholarly journals Substrate specificity of an aflatoxin-metabolizing aldehyde reductase

1995 ◽  
Vol 312 (2) ◽  
pp. 535-541 ◽  
Author(s):  
E M Ellis ◽  
J D Hayes
Keyword(s):  
Substrate Specificity ◽  
High Activity ◽  
Rat Liver ◽  
Aflatoxin B1 ◽  
Succinic Semialdehyde ◽  
Aldehyde Reductase ◽  
Aliphatic Aldehydes ◽  
Alpha Beta ◽  
Low Activity

The enzyme from rat liver that reduces aflatoxin B1-dialdehyde exhibits a unique catalytic specificity distinct from that of other aldo-keto reductases. This enzyme, designated AFAR, displays high activity towards dicarbonyl-containing compounds with ketone groups on adjacent carbon atoms; 9,10-phenanthrenequinone, acenaphthenequinone and camphorquinone were found to be good substrates. Although AFAR can also reduce aromatic and aliphatic aldehydes such as succinic semialdehyde, it is inactive with glucose, galactose and xylose. The enzyme also exhibits low activity towards alpha, beta-unsaturated carbonyl-containing compounds. Determination of the apparent Km reveals that AFAR has highest affinity for 9,10-phenanthrenequinone and succinic semialdehyde, and low affinity for glyoxal and DL-glyceraldehyde.

scholarly journals Purification from rat liver of a novel constitutively expressed member of the aldo-keto reductase 7 family that is widely distributed in extrahepatic tissues

2000 ◽  
Vol 348 (2) ◽  
pp. 389-400 ◽  
Author(s):  
Vincent P. KELLY ◽  
Linda S. IRELAND ◽  
Elizabeth M. ELLIS ◽  
John D. HAYES
Keyword(s):  
Rat Liver ◽  
Aflatoxin B1 ◽  
Single Gene ◽  
Reversed Phase ◽  
Cross Reactivity ◽  
Rat Tissues ◽  
Succinic Semialdehyde ◽  
Aldehyde Reductase ◽  
Cibacron Blue ◽  
Sds Page

Antiserum raised against human aflatoxin B1 aldehyde reductase 1 (hAFAR1) has been used to identify a previously unrecognized rat aldo-keto reductase (AKR). This novel enzyme is designated rat aflatoxin B1 aldehyde reductase 2 (rAFAR2) and it characteristically migrates faster during SDS/PAGE than does the archetypal ethoxyquin-inducible rAFAR protein (now called rAFAR1). Significantly, rAFAR2 is essentially unreactive with polyclonal antibodies raised against rAFAR1. Besides its distinct electrophoretic and immunochemical properties, rAFAR2 appears to be regulated differently from rAFAR1 as it is expressed in most rat tissues and does not appear to be induced by ethoxyquin. Multiple forms of rAFAR2 have been identified. Anion-exchange chromatography on Q-Sepharose, followed by adsorption chromatography on columns of Matrex Orange A and Cibacron Blue, have been employed to purify rAFAR2 from rat liver cytosol. The Q-Sepharose chromatography step resulted in the resolution of rAFAR2 into three peaks of AKR activity, two of which were purified and shown to be capable of catalysing the reduction of 2-carboxybenzaldehyde, succinic semialdehyde, 4-nitrobenzaldehyde and 9,10-phenathrenequinone. The two most highly purified rAFAR2-containing preparations eluted from the Cibacron Blue column were 91 and 98% homogeneous. Analysis of these by SDS/PAGE indicated that the least anionic (peak CBA5) comprised a polypeptide of 37.0 kDa, whereas the most anionic (peak CBA6) contained two closely migrating polypeptides of 36.8 and 37.0 kDa; by contrast, in the present study, rAFAR1 was estimated by SDS/PAGE to be composed of 38.0 kDa subunits. Final purification of the 37 kDa polypeptide in CBA5 and CBA6 was accomplished by reversed-phase HPLC. Partial proteolysis of the two preparations of the 37 kDa polypeptide with Staphylococcus aureus V8 protease yielded fragments of identical size, suggesting that they represent the product of a single gene. Furthermore, the peptide maps from CBA5 and CBA6 differed substantially from that yielded by rAFAR1, indicating that they are genetically distinct from the inducible reductase. A peptide generated by CNBr digestion of the 37 kDa polypeptide from CBA6 was shown by Edman degradation to share 88% sequence identity with residues Tyr168-Leu183 of rAFAR1. This provides evidence that the rat protein identified by its cross-reactivity with anti-hAFAR1 serum is an additional member of the AKR7 family.

scholarly journals Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members

1999 ◽  
Vol 343 (2) ◽  
pp. 487-504 ◽  
Author(s):  
Tania O'CONNOR ◽  
Linda S. IRELAND ◽  
David J. HARRISON ◽  
John D. HAYES
Keyword(s):  
Small Intestine ◽  
Substrate Specificity ◽  
Western Blotting ◽  
Aflatoxin B1 ◽  
Specific Activity ◽  
Family Members ◽  
Human Kidney ◽  
Aldehyde Reductase ◽  
Aliphatic Aldehydes ◽  
Kidney Liver

Complementary DNA clones encoding human aflatoxin B1 aldehyde reductase (AKR7A2), aldehyde reductase (AKR1A1), aldose reductase (AKR1B1), dihydrodiol dehydrogenase 1 (AKR1C1) and chlordecone reductase (AKR1C4) have been expressed in Escherichia coli. These members of the aldo-keto reductase (AKR) superfamily have been purified from E. coli as recombinant proteins. The recently identified AKR7A2 was shown to differ from the AKR1 isoenzymes in being able to catalyse the reduction of 2-carboxybenzaldehyde. Also, AKR7A2 was found to exhibit a narrow substrate specificity, with activity being restricted to succinic semialdehyde (SSA), 2-nitrobenzaldehyde, pyridine-2-aldehyde, isatin, 1,2-naphthoquinone (1,2-NQ) and 9,10-phenanthrenequinone. In contrast, AKR1A1 reduces a broad spectrum of carbonyl-containing compounds, displaying highest specific activity for SSA, 4-carboxybenzaldehyde, 4-nitrobenzaldehyde, pyridine-3-aldehyde, pyridine-4-aldehyde, 4-hydroxynonenal, phenylglyoxal, methylglyoxal, 2,3-hexanedione, 1,2-NQ, 16-ketoestrone and D-glucuronic acid. Comparison between the kinetic properties of AKR7A2 and AKR1A1 showed that both recombinant enzymes exhibited roughly similar kcat/Km values for SSA, 1,2-NQ and 16-ketoestrone. Many of the compounds which are substrates for AKR1A1 also serve as substrates for AKR1B1, though the latter enzyme was shown to display a specific activity significantly less than that of AKR1A1 for most of the aromatic and aliphatic aldehydes studied. Neither AKR1C1 nor AKR1C4 was found to possess high reductase activity towards aliphatic aldehydes, aromatic aldehydes, aldoses or dicarbonyls. However, unlike AKR1A1 and AKR1B1, both AKR1C1 and AKR1C4 were able to catalyse the oxidation of 1-acenaphthenol and, in addition, AKR1C4 could oxidize di- and tri-hydroxylated bile acids. Specific antibodies raised against AKR7A2, AKR1A1, AKR1B1, AKR1C1 and AKR1C4 have been used to show the presence of all of the reductases in human hepatic cytosol; the levels of AKR1B1 and AKR1C1 were markedly elevated in livers with alcohol-associated injury, and indeed AKR1B1 was only detectable in livers with evidence of alcoholic liver disease. Western blotting of extracts from brain, heart, kidney, liver, lung, prostate, skeletal muscle, small intestine, spleen and testis showed that AKR7A2 is present in all of the organs examined, and AKR1B1 is similarly widely distributed in human tissues. These experiments revealed however, that the expression of AKR1A1 is restricted primarily to brain, kidney, liver and small intestine. The AKR1C family members proved not to be as widely expressed as the other reductases, with AKR1C1 being observed in only kidney, liver and testis, and AKR1C4 being found in liver alone. As human kidney is a rich source of AKR, the isoenzymes in this organ have been studied further. Anion-exchange chromatography of human renal cytosol on Q-Sepharose allowed resolution of AKR1A1, AKR1B1, AKR1C1 and AKR7A2, as identified by substrate specificity and Western blotting. Immunohistochemistry of human kidney demonstrated that AKR7A2 is expressed in a similar fashion to the AKR1 family members in proximal and distal convoluted renal tubules. Furthermore, both AKR7A2 and AKR1 members were expressed in renal carcinoma cells, suggesting that these groups of isoenzymes may be engaged in related physiological functions.

Determination of Aflatoxin B1–DNA Adduct in Rat Liver by Enzyme Immunoassay

The Analyst ◽  
1997 ◽  
Vol 122 (6) ◽  
pp. 609-613 ◽  
Author(s):  
T. Vidyasagar ◽  
N. Sujatha ◽  
R. B. Sashidhar
Keyword(s):  
Enzyme Immunoassay ◽  
Rat Liver ◽  
Aflatoxin B1 ◽  
Dna Adduct

scholarly journals A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant

1993 ◽  
Vol 292 (1) ◽  
pp. 13-18 ◽  
Author(s):  
D J Judah ◽  
J D Hayes ◽  
J C Yang ◽  
L Y Lian ◽  
G C K Roberts ◽  
...  
Keyword(s):  
Enzyme Activity ◽  
Rat Liver ◽  
Aflatoxin B1 ◽  
British Library ◽  
Aldehyde Reductase ◽  
Ph Values ◽  
Development Of Resistance ◽  
Neoplastic Lesions ◽  
Anti Oxidant ◽  
Rat Livers

In contrast with fractions from control animals, an aldehyde reductase, which catalyses the reduction of aflatoxin B1-dihydrodiol, in the dialdehyde form at physiological pH values, to aflatoxin B1-dialcohol, is expressed in cytosolic fractions prepared from rat livers bearing pre-neoplastic lesions, or following treatment with the anti-oxidant ethoxyquin. This expression parallels the development of resistance to the toxin. Unlike the aflatoxin B1-dihydrodiol, the dialcohol does not undergo binding to protein. This enzyme activity could play a mechanistic role in hepatocarcinogenesis and chemoprotection in the rat. Correlated n.m.r. and m.s. spectra are provided in Supplementary Publication SUP 50171 (3 pages), which has been deposited at the British Library Document Supply Centre, Boston Spa, Wetherby, West Yorkshire LS23 7BQ, U.K., from whom copies can be obtained on the terms indicated in Biochem. J. (1993) 289, 9.

scholarly journals γ-butyrobetaine in tissues and serum of fed and starved rats determined by an enzymic radioisotopic procedure

1984 ◽  
Vol 220 (3) ◽  
pp. 701-706 ◽  
Author(s):  
H Noël ◽  
R Parvin ◽  
S V Pande
Keyword(s):  
High Activity ◽  
Rat Liver ◽  
Skeletal Muscles ◽  
Adult Rats ◽  
Male Adult ◽  
Low Concentration ◽  
High Affinity ◽  
The Mean

A method for the determination of picomole quantities of gamma-butyrobetaine and its application for the determination of gamma-butyrobetaine distribution in tissues are described. The method is based on the quantitative conversion of gamma-butyrobetaine into carnitine by using a 50-60%-satd.-(NH4)2SO4 fraction of rat liver supernatant as the source of gamma-butyrobetaine hydroxylase [4-trimethylaminobutyrate,2-oxoglutarate:oxygen oxidoreductase (3-hydroxylating), EC 1.14.11.1]; the carnitine formed is then measured enzymically. The mean gamma-butyrobetaine content, as nmol/g wet wt. of tissue, ranged from a low of 4.6 in livers to a high of 12.3 in hearts of normal fed male adult rats. Starvation for 48 h did not affect the gamma-butyrobetaine concentration in serum, liver and brain, but that in skeletal muscles, kidney and heart was increased. These data are in line with the present views that most tissues are able to produce gamma-butyrobetaine, and show that starvation enhances the synthesis and/or the retention of this compound in many tissues. The observed high affinity of gamma-butyrobetaine hydroxylase for gamma-butyrobetaine (Km 7 microM), the high activity of this enzyme and the low concentration of gamma-butyrobetaine in liver indicate that gamma-butyrobetaine availability is one of the factors that normally limit carnitine synthesis.

scholarly journals Novel homodimeric and heterodimeric rat γ-hydroxybutyrate synthases that associate with the Golgi apparatus define a distinct subclass of aldo-keto reductase 7 family proteins

2002 ◽  
Vol 366 (3) ◽  
pp. 847-861 ◽  
Author(s):  
Vincent P. KELLY ◽  
Philip J. SHERRATT ◽  
Dorothy H. CROUCH ◽  
John D. HAYES
Keyword(s):  
Amino Acids ◽  
Golgi Apparatus ◽  
High Activity ◽  
Rat Liver ◽  
Expressed Sequence Tag ◽  
Secretory Process ◽  
Succinic Semialdehyde ◽  
Sequence Identity ◽  
Terminal Domain ◽  
N Terminus

The aldo-keto reductase (AKR) 7 family is composed of the dimeric aflatoxin B1 aldehyde reductase (AFAR) isoenzymes. In the rat, two AFAR subunits exist, designated rAFAR1 and rAFAR2. Herein, we report the molecular cloning of rAFAR2, showing that it shares 76% sequence identity with rAFAR1. By contrast with rAFAR1, which comprises 327 amino acids, rAFAR2 contains 367 amino acids. The 40 extra residues in rAFAR2 are located at the N-terminus of the polypeptide as an Arg-rich domain that may form an amphipathic α-helical structure. Protein purification and Western blotting have shown that the two AFAR subunits are found in rat liver extracts as both homodimers and as a heterodimer. Reductase activity in rat liver towards 2-carboxybenzaldehyde (CBA) was resolved by anion-exchange chromatography into three peaks containing rAFAR1-1, rAFAR1-2 and rAFAR2-2 dimers. These isoenzymes are functionally distinct; with NADPH as cofactor, rAFAR1-1 has a low Km and high activity with CBA, whereas rAFAR2-2 exhibits a low Km and high activity towards succinic semialdehyde. These data suggest that rAFAR1-1 is a detoxication enzyme, while rAFAR2-2 serves to synthesize the endogenous neuromodulator γ-hydroxybutyrate (GHB). Subcellular fractionation of liver extracts showed that rAFAR1-1 was recovered in the cytosol whereas rAFAR2-2 was associated with the Golgi apparatus. The distinct subcellular localization of the rAFAR1 and rAFAR2 subunits was confirmed by immunocytochemistry in H4IIE cells. Association of rAFAR2-2 with the Golgi apparatus presumably facilitates secretion of GHB, and the novel N-terminal domain may either determine the targeting of the enzyme to the Golgi or regulate the secretory process. A murine AKR protein of 367 residues has been identified in expressed sequence tag databases that shares 91% sequence identity with rAFAR2 and contains the Arg-rich extended N-terminus of 40 amino acids. Further bioinformatic evidence is presented that full-length human AKR7A2 is composed of 359 amino acids and also possesses an additional N-terminal domain. On the basis of these observations, we conclude that AKR7 proteins can be divided into two subfamilies, one of which is a Golgi-associated GHB synthase with a unique, previously unrecognized, N-terminal domain that is absent from other AKR proteins.

Quantitative Determination of 1-131, Cs-137, and Ba-140 in Milk: Collaborative Studies

1982 ◽  
Vol 65 (5) ◽  
pp. 1039-1043
Author(s):  
Frederick G D Shuman ◽  
David G Easterly ◽  
Edmond J Baratta
Keyword(s):  
High Activity ◽  
Gamma Ray ◽  
Collaborative Study ◽  
Official Method ◽  
Collaborative Studies ◽  
Coefficients Of Variation ◽  
The Mean ◽  
Method Bias ◽  
Low Activity

Abstract The official method for Cs-137 in milk by gamma-ray spectroscopy was extended to include 1-131 and Ba- 140. A collaborative study was performed on this method applied to 1-131 concentration in cow's milk; the original collaborative study of the method including all 3 nuclides was reviewed. In the 1-131 study, 1 aliquot of a milk sample containing 82 pCi/L was sent to each of 60 laboratories for triplicate analyses. From 40 responses, the mean of the reported values was 81.6 pCi/L, indicating a method bias below the 5% statistical detectability limit. Within- and between-laboratory coefficients of variation (CVs) were 7 and 8%, respectively. In the 3-nuclide study, 2 samples were sent to 25 laboratories for triplicate analyses; one sample contained 633,305, and 515 pCi/L, respectively, of 1-131, Cs-137, and Ba-140 and the other contained 98,52, and 72 pCi/L. For the high-activity sample, within-laboratory CVs were 4-5% for the 3 nuclides and between-laboratory CVs were 4-7%. For the low-activity sample, the corresponding results were 6-9% and 8-16%. The method bias was statistically significant at 95% confidence only for Cs-137 in the high-activity sample; reported results were 3% below the known concentration. The extended method was adopted official first action.

scholarly journals Determinants of specificity for aflatoxin B1-8,9-epoxide in Alpha-class glutathione S-transferases

1999 ◽  
Vol 339 (1) ◽  
pp. 95-101 ◽  
Author(s):  
Paul D. McDONAGH ◽  
David J. JUDAH ◽  
John D. HAYES ◽  
Lu-Yun LIAN ◽  
Gordon E. NEAL ◽  
...  
Keyword(s):  
Crystal Structure ◽  
Substrate Specificity ◽  
High Activity ◽  
Aflatoxin B1 ◽  
Active Site ◽  
Homology Modelling ◽  
Three Dimensional ◽  
Glutathione S Transferase ◽  
Glutathione S Transferases ◽  
Aspartate Residue

We have used homology modelling, based on the crystal structure of the human glutathione S-transferase (GST) A1-1, to obtain the three-dimensional structures of rat GSTA3 and rat GSTA5 subunits bound to S-aflatoxinyl–glutathione. The resulting models highlight two residues, at positions 208 and 108, that could be important for determining, either directly or indirectly, substrate specificity for aflatoxin-exo-8,9-epoxide among the Alpha-class GSTs. Residues at these positions were mutated in human GSTA1-1 (Met-208, Leu-108), rat GSTA3-3 (Glu-208, His-108) and rat GSTA5-5 (Asp-208, Tyr-108): in the active rat GSTA5-5 to those in the inactive GSTA1-1; and in the inactive human GSTA1-1 and rat GSTA3-3 to those in the active rat GSTA5-5. These studies show clearly that, in all three GSTs, an aspartate residue at position 208 is a prerequisite for high activity in aflatoxin-exo-8,9-epoxide conjugation, although this alone is not sufficient; other residues in the vicinity, particularly residues 103–112, are important, perhaps for the optimal orientation of the aflatoxin-exo-8,9-epoxide in the active site for catalysis to occur.

scholarly journals Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo–keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase

1998 ◽  
Vol 332 (1) ◽  
pp. 21-34 ◽  
Author(s):  
Linda S. IRELAND ◽  
David J. HARRISON ◽  
Gordon E. NEAL ◽  
John D. HAYES
Keyword(s):  
Aflatoxin B1 ◽  
Human Liver ◽  
Reductase Activity ◽  
Structural Features ◽  
Aldehyde Group ◽  
Succinic Semialdehyde ◽  
Aldehyde Reductase ◽  
Extrahepatic Tissues ◽  
Pharmaceutically Active Compound

The masking of charged amino or carboxy groups by N-phthalidylation and O-phthalidylation has been used to improve the absorption of many drugs, including ampicillin and 5-fluorouracil. Following absorption of such prodrugs, the phthalidyl group is hydrolysed to release 2-carboxybenzaldehyde (2-CBA) and the pharmaceutically active compound; in humans, 2-CBA is further metabolized to 2-hydroxymethylbenzoic acid by reduction of the aldehyde group. In the present work, the enzyme responsible for the reduction of 2-CBA in humans is identified as a homologue of rat aflatoxin B1-aldehyde reductase (rAFAR). This novel human aldo–keto reductase (AKR) has been cloned from a liver cDNA library, and together with the rat protein, establishes the AKR7 family of the AKR superfamily. Unlike its rat homologue, human AFAR (hAFAR) appears to be constitutively expressed in human liver, and is widely expressed in extrahepatic tissues. The deduced human and rat protein sequences share 78% identity and 87% similarity. Although the two AKR7 proteins are predicted to possess distinct secondary structural features which distinguish them from the prototypic AKR1 family of AKRs, the catalytic- and NADPH-binding residues appear to be conserved in both families. Certain of the predicted structural features of the AKR7 family members are shared with the AKR6 β-subunits of voltage-gated K+-channels. In addition to reducing the dialdehydic form of aflatoxin B1-8,9-dihydrodiol, hAFAR shows high affinity for the γ-aminobutyric acid metabolite succinic semialdehyde (SSA) which is structurally related to 2-CBA, suggesting that hAFAR could function as both a SSA reductase and a 2-CBA reductase in vivo. This hypothesis is supported in part by the finding that the major peak of 2-CBA reductase activity in human liver co-purifies with hAFAR protein. The cDNA sequence for human AFAR has been assigned by GenBank the accession number AF026947.

Sign in / Sign up

Export Citation Format

Share Document